[EN] RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] INHIBITEURS DE RET, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2020114494A1
公开(公告)日:2020-06-11
Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.
Bulky diarylammonium arenesulfonates as mild and extremely active dehydrative ester condensation catalysts
作者:Akira Sakakura、Shoko Nakagawa、Kazuaki Ishihara
DOI:10.1016/j.tet.2005.09.059
日期:2006.1
especially large-scale, fundamental reactions like estercondensations, are highly desirable for many reactions. Bulky diarylammonium pentafluorobenzenesulfonates and tosylates serve as extremely active dehydration catalysts for the estercondensation reaction of carboxylicacids with equimolaramounts of sterically demanding alcohols and acid-sensitive alcohols. Typically, the esterification reaction is performed
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria
novel series of coumarin derivatives 6a-o, bearing isoxazolemoieties were designed and synthesized. After that, they were evaluated for melanin synthesis in murine B16 cells and inhibitory effect on the growth of CA (Candida albicans), EC (Escherichia coli), SA (Staphylococcus aureus). It was found that eleven compounds (6b-f, 6j-o) showed a better activity on melanin synthesis than positive control
Tetrahydroquinoline derivatives useful for neurodegenerative disorders
申请人:Merck Sharp & Dohme, Ltd.
公开号:US05231102A1
公开(公告)日:1993-07-27
A class of 1,2,3,4-tetrahydroquinolines possessing at least one substituent, or a spirocyclic moiety, at the 4-position, and an acidic group or a group convertible thereto in vivo at the 2-position, are specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment and/or prevention of neurodegenerative disorders.